BioWorld

Dec. 4, 2006

As Pfizer Changes, Biotech Partners Seem Unaffected

A loss of exclusivity, strong competition and a changing market led Pfizer Inc. to cut its U.S. sales force by 20 percent last week, yet analysts say the move should have little impact - if any - on the biotech community. (BioWorld Today) Read More

House Committee To Take Up Uncertainties Around EPO Use

Will 2007 Have Tidings Of Joy? Some Thoughts On Next Year

Cousin Of Singulair, Is Celebrex Useful In Cardiac Hypertrophy?

Appointments And Advancements

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...